key: cord-0768305-3e1y65wf authors: Suryadevara, Naveenchandra; Gilchuk, Pavlo; Zost, Seth J.; Mittal, Nikhil; Zhao, Li Leyna; Crowe, James E.; Carnahan, Robert H. title: Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape date: 2022-04-22 journal: STAR Protoc DOI: 10.1016/j.xpro.2022.101387 sha: 15f8e37e986d37c1dc2b703251f51bdbe170dd97 doc_id: 768305 cord_uid: 3e1y65wf Real-time cell analysis (RTCA) enables high-throughput, quantitative kinetic measurements of cytopathic effect (CPE) in virus-infected cells. Here we detail a RTCA approach for assessing antibody neutralization. We describe how to evaluate the neutralizing potency of monoclonal antibodies (mAbs) and identify viral escape mutants to antibody neutralization for severe respiratory syndrome coronavirus 2 (SARS-CoV-2). For complete details on the use and execution of this protocol, please refer to Zost et al., 2020 and Suryadevara et al., 2021. In recent years, monoclonal antibodies (mAbs) increasingly have been deployed as therapeutic countermeasures against viral infections. Antibodies have been approved for respiratory syncytial virus (Johnson et al., 1997) , Ebola virus (Corti et al., 2016a; Pascal et al., 2018) and human immunodeficiency virus (HIV) (Reimann et al., 1997) . There are dozens of human mAbs in clinical trials against additional viral targets, such as influenza virus (Laursen and Wilson, 2013) , Marburg virus (Flyak et al., 2015) , Zika virus (ZIKV) , Lassa virus (Robinson et al., 2016) , Middle East respiratory syndrome coronavirus (MERS-CoV) (Corti et al., 2016b) , poxviruses (Gilchuk et al., 2016) , and Nipah virus (Geisbert et al., 2014) . The current SARS-CoV-2 pandemic has further highlighted the importance of the rapid development of human antiviral mAbs for COVID-19 prevention and treatment. The protocol describes in vitro monoclonal antibody neutralization assays and escape mutant identification using a RTCA assaybased workflow with a replication-competent recombinant vesicular stomatitis virus (rVSV) expressing the SARS-CoV-2 spike protein (rVSV-SARS-CoV-2) Gilchuk et al., 2022) (Figure 1) . RTCA-based neutralization is monitored by measuring changes in cell impedance caused by virus infection of cell monolayers and displayed as cell index. Careful evaluation is required when selecting cell lines for RTCA, as many viruses do not replicate or cause cytopathic effects (CPE) in certain cell lines due to host-range restriction factors, such as the lack of an authentic cell-surface receptor to facilitate attachment and entry (Hoffmann et al., 2020) . For instance, our laboratory has used this technique for identifying and characterizing neutralizing antibodies against Ebola virus (Gilchuk et al., 2021b; Gilchuk et al., 2020b) , Zika virus (Gilchuk et al., 2020a) , influenza virus (Gilchuk et al., 2021a) , and Nipah virus (Doyle et al., 2021) . Timing: [30 min] Prepare cell culture medium in a biosafety cabinet. To make a 10% FBS solution, add 55 mL FBS into 500 mL high-glucose DMEM supplemented with 1% penicillin/streptomycin solution. Use 10% FBS DMEM for cell propagation. To make 2% FBS DMEM, add 10 mL FBS into 490 mL high-glucose DMEM supplemented with 1% penicillin/streptomycin solution. Use 2% FBS DMEM for mAb dilutions, neutralization assays, and experiment to identify antibody escape mutant viruses. Timing: [8-12 days] Sequences encoding antibody variable genes are synthesized by a commercial DNA synthesis service and cloned into an IgG1 expression plasmid (pTwist CMV BetaGlobin WPRE Neo) were used for mAb expression in mammalian cell culture for secretion into cell supernatant. We previously described a microscale expression approach for mAbs in 1 mL Expifectamine™ Chinese Hamster Ovary (ExpiCHO; Thermo Fisher Scientific) cell cultures in 96-well plates (Gilchuk et al., 2020a) . For larger-scale mAb expression, we performed transfection in larger volume suspensions (15-20 mL per antibody) of ExpiCHO cell cultures using the Gibco ExpiCHO Expression System and protocol for 50 mL Mini J o u r n a l P r e -p r o o f Bioreactor tubes (Corning), as described by the vendor. Culture supernatants were purified using HiTrap MabSelect SuRe (Cytiva, formerly GE Healthcare Life Sciences) on a 24column parallel protein chromatography system (Protein BioSolutions). Purified mAb IgG1 proteins were buffer-exchanged into PBS, concentrated using Amicon Ultra-4 50-kDa centrifugal filter units (Millipore Sigma), and stored at 4 °C until use (Gilchuk et al., 2020a) . Timing: [1-2hr] Quantification of purified mAbs was performed by UV spectrophotometry using a spectrophotometer (NanoDrop, ND-8000 thermo scientific) and accounting for the extinction coefficient of human IgG. The generation of a replication-competent rVSV expressing SARS-CoV-2 spike protein with a 21 amino-acid C-terminal deletion that replaces the VSV G protein (VSV-SARS-CoV-2) was described previously . The spike protein-expressing VSV virus was propagated in MA104 cell culture monolayers (African green monkey, American Type Culture Collection [ATCC] CRL-2378.1) as described previously , and viral stocks were titrated on Vero The xCELLigence RTCA MP (Multiple Plates) instrument (Agilent Technologies) uses impedance biosensors for continuous label-free monitoring of cell behaviors that alter cellular impedance. Depending on the exact model of instrument used, cells in each well of one or six parallel plates can be simultaneously monitored in real time. The multiple plate format is ideal for large screening workflows in numerous assay modalities. The instrument with E-plates operates in a standard CO2 cell culture incubator with the control unit housed outside the incubator. Step-by-step method details: a. Thaw cryopreserved vial of Vero cells by gently swirling in 37°C water bath until few ice crystals are present; do not submerge the cap. Wipe the vial with 70% ethanol and place it into the biosafety cabinet. The water bath should be regularly calibrated for accurate temperature. ii. Aspirate growth medium from the flask and discard. iii. Wash cell layer with trypsin to remove residual growth medium (coat surface then immediately aspirate and discard). J o u r n a l P r e -p r o o f iv. Add 2mL of 0.25% trypsin-EDTA to the flask to cover the cells and place at 37°C for 3 to 5 minutes (or until cells detach when viewed by bright-field microscopy). Critical step: Use fresh cells at 80 to 90% confluency. Do not over-incubate cells with trypsin. v. Add warmed growth medium (10% FBS DMEM) to dilute the original trypsin volume at least five-fold. For T-225 flasks, add ~10 mL of growth medium, then complete steps in (f). After the cells have been resuspended, add the remaining growth medium to ensure a five-fold dilution of trypsin. vi. Rinse flask surface to ensure all trypsin is deactivated. Count the cell suspension and perform the following calculations: a. Use the viable cell density to calculate the total viable cells in the cell suspension (viable cell density * volume = total cells viable). i. Prepare cells at a density of 0.3 to 0.35  10 6 cells/mL (which translates to ~18,000 cells/50 µL) and add 50 µL/well to the plate. Critical step: Use fresh cells at 80 to 90% confluency. Seeding the plate at the proper cell density is essential. Using too many cells, cells at excess density, or cells that are excessively passaged could result in experimental artifacts. Also, use 2% FBS containing DMEM for assay. a. To start an experiment, open instrument software, select a cradle, go to the first tab labeled as "Experiment" and label the experiment to save in the desired location. b. In the "Layout" tab, prepare the scheme of the experiment as shown in Figure 3A . c. In the "Schedule" tab, add three steps using the 'Add Step' button or by rightclicking. i. The first step is to read the background with the medium only. ii. The second step is for cellular adherence (plating cells and allowing them to create a monolayer). iii. The third step is for measuring the impedance after virus addition. Critical step: Before running the actual assay, it is recommended that a titration of the virus be done to establish the dilution of the virus stock suitable for the assay. We found 0.1 multiplicity of infection (MOI, see Figure 2 ) x. RTCA IC50 values are determined by nonlinear regression analysis using Prism software. See Figure 4 for representative mAb neutralization curves are calculated using e using nonlinear fit with variable slope analysis (Gilchuk et al., 2020a) . a. To generate escape mutant virus, repeat steps 2a, and steps 3a through 3t and monitor for the escape of virus. x. Centrifuge at 6,000 x g (8,000 rpm) for 1 min. Store RNA samples in a clean labeled iii. Let beads air dry on the magnet for 2 min. iv. Remove from the magnet and resuspend beads in 50 µL of elution buffer. v. Add tubes back to the magnet and incubate for 2 min. gg. Remove supernatant and place in clean, labeled 1.5 ml Lobind microcentrifuge tube and store at -20C. Pause Point: Purified PCR products can be stored at 4C for several days or -20C for months. hh. Analyze cDNA on 0.8% agarose gel to verify successful amplification, purity, and size before sequencing. i. Mix 1 µL of purified PCR sample with 10 µL loading dye supplied by Agilent. ii. Similarly, mix 1 µL of standard provided with 10 µL loading dye. ii. Shake before loading samples to mix. Analyze the results. Usually, PCR will yield a single DNA band with a size of 4 kilobases. jj. After obtaining the sequencing results, analyze the sequences by aligning to the wildtype virus sequence using appropriate software to identify the sequence changes in the variants. The inclusion of both positive (COV2-2196) and negative controls (rDENV-2D222) is critical in calculating the percentage of neutralization in the assay. An optimal negative control is vital for assay success for novel targets lacking a clear positive control. An mAb that recognizes an unrelated target antigen can be used as a negative control. J o u r n a l P r e -p r o o f This protocol can efficiently identify neutralizing mAbs against the SARS-CoV-2 virus and rapidly generate, isolate, and evaluate mutants that escape antibody neutralization. RTCA assay is a high-throughput technique that can identify SARS-CoV-2 neutralizing antibodies within 48 to 72 hrs, and results are highly correlated with conventional assays (Gilchuk et al., 2020a; Gilchuk et al., 2022) . Normalized cellular index (CI) values at the endpoint (48 hrs after incubation with the virus) were determined using the RTCA software version 2.1.0 (Agilent Technologies). Results are expressed as percent neutralization in the presence of the respective mAb relative to control wells with no CPE minus CI values from control wells with maximum CPE. RTCA IC50 values were determined by nonlinear regression analysis using Prism software. Engineering and generating a replication-competent chimeric VSV reagent to study entry and neutralization of SARS-CoV-2 at biosafety level 2 is key to this protocol. Expression of the glycoprotein of interest is often accomplished by plasmid transfection, which requires optimization to minimize batch variation. It is also unknown how spike protein display on a heterologous virus impacts viral entry, antibody recognition, and antibody neutralization compared to authentic coronavirus. This question is important because neutralization assays are used to establish correlates of protection for vaccine and antibody-based countermeasures, and most manufacturers lack access to high-containment laboratories to test antibody responses against highly pathogenic Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2 Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein Mechanism of human antibodymediated neutralization of Marburg virus Therapeutic treatment of Nipah virus infection Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections Human antibody recognition of H7N9 influenza virus HA following natural infection Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics Pan-ebolavirus protective therapy by two multifunctional human antibodies Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization Standardized two-step testing of antibody activity in COVID-19 convalescent plasma A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus Broadly neutralizing antibodies against influenza viruses Enhancing dengue virus maturation using a stable furin over-expressing cell line Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties Most neutralizing human monoclonal J o u r n a l P r e -p r o o f antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice Persistence of Circulating Memory B Cell Clones with Potential for Dengue Virus Disease Enhancement for Decades following Infection Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein • Rapidly identify potent neutralizing antibodies from hundreds of candidates.• Quickly identify and isolate virus variants that escape from antibody neutralization.• Assay provides facile pathway to identify critical residues that mediate viral escape.• Avoids virus-specific reagents (ex. reporter viruses) and labor-intensive approaches.J o u r n a l P r e -p r o o f